Mesoblast clears FDA path as Ryoncil growth funds new clinical milestones

• Ryoncil first-quarter net revenue rose 44% to US$28 million, subject to financial close and audit
• Net operating cash use fell to US$2.128 million from US$14.9 million a year earlier
• All patients completed treatment in the 350-patient rexlemestrocel-L Phase 3 low back pain trial
• FDA confirmed Mesoblast may proceed with a BLA filing for life-threatening GI bleeding in LVAD-supported heart failure patients